ACADIA Pharmaceuticals Inc (ACAD) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
Total Cash From Operating Activities Chart for ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc (ACAD) operating cash flow for FY2025 was USD 109.8M, a -30.4% change from FY2024. ACADIA Pharmaceuticals Inc's operating cash flow moved from USD -9.2M in 2002 to USD 109.8M in 2025 over 23 years.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $3.39B
- Implied Share Price
- $19.80
- Enterprise Value
- $3.50B
- Revenue (TTM)
- $1.14B
- EBITDA
- $98.39M
- Profit Margin
- 33.42%
- Trailing P/E
- 8.57
- Forward P/E
- 25.19
- Price/Book (MRQ)
- 3.35
- Price/Sales (TTM)
- 3.00
- EV/EBITDA
- 35.53
- EV/Revenue
- 3.07
- Dividend Yield
- —
- Book Value
- $7.59
- Free Cash Flow (FY2025)
- $105.15M
- Free Cash Flow Yield
- 3.10%
Snapshot as of 20th October 2026 — not point-in-time controlled, may lag the live market by a few days.